EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inhibition of dynamin‐related protein 1‐filamin interaction improves systemic glucose metabolism

Yuri Kato iD, Kohei Ariyoshi, Yasunobu Nohara, Naoya Matsunaga, Tsukasa Shimauchi, Naoya Shindo, Akiyuki Nishimura, Xinya Mi, Sang Geon Kim, Tomomi Ide, Eiji Kawanishi, Akio Ojida und 3 weitere

British Journal of Pharmacology · 2024

DOI: 10.1111/bph.16487 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Pharmacology, 2024. Verfasst von Yuri Kato und 14 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan. Hauptthemen laut MEDLINE: Dynamins, Dihydropyridines, Diabetes Mellitus, Experimental. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Corporation, Grant-in-Aid for Scientific Research on Innovative Areas (A).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Maintaining mitochondrial quality is attracting attention as a new strategy to treat diabetes and diabetic complications. We previously reported that mitochondrial hyperfission by forming a protein complex between dynamin‐related protein (Drp) 1 and filamin, mediates chronic heart failure and cilnidipine, initially developed as an L/N‐type Ca 2+ channel blocker, improves heart failure by inhibiting Drp1‐filamin protein complex. We investigated whether cilnidipine improves hyperglycaemia of various diabetic mice models. Experimental Approach Retrospective analysis focusing on haemoglobin A1c (HbA1c) was performed in hypertensive and hyperglycaemic patients taking cilnidipine and amlodipine. After developing diabetic mice by streptozotocin (STZ) treatment, an osmotic pump including drug was implanted intraperitoneally, followed by weekly measurements of blood glucose levels. Mitochondrial morphology was analysed by electron microscopy. A Ca 2+ channel‐insensitive cilnidipine derivative (1,4‐dihydropyridine [DHP]) was synthesized and its pharmacological effect was evaluated using obese ( ob/ob ) mice fed with high‐fat diet (HFD). Key Results In patients, cilnidipine was superior to amlodipine in HbA1c lowering effect. Cilnidipine treatment improved systemic hyperglycaemia and mitochondrial morphological abnormalities in STZ‐exposed mice, without lowering blood pressure. Cilnidipine failed to improve hyperglycaemia of ob/ob mice, with suppressing insulin secretion. 1,4‐DHP improved hyperglycaemia and mitochondria abnormality in ob/ob mice fed HFD. 1,4‐DHP and cilnidipine improved basal oxygen consumption rate of HepG2 cells cultured under 25 mM glucose. Conclusion and implications Inhibition of Drp1‐filamin protein complex formation becomes a new strategy for type 2 diabetes treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DynaminsDihydropyridinesDiabetes Mellitus, ExperimentalAnimalsHumansMaleMiceMice, Inbred C57BLHyperglycemiaGlycated HemoglobinAmlodipineFemaleRetrospective StudiesMiddle AgedBlood GlucoseAgedCalcium Channel BlockersMitochondriaHypertensionGlucoseMice, Obese

Stichwörter der Autor:innen

Drp1filamininsulinmitochondria quality controltype2 diabetes

Substanzen

DynaminsDihydropyridinescilnidipineGlycated HemoglobinAmlodipineBlood GlucoseCalcium Channel BlockersDNM1L protein, humanGlucose

Autor:innen und Institutionen

  • Graduate School of Pharmaceutical Sciences, Kyushu University, Fukuoka, Japan.
  • Faculty of Advanced Science and Technology, Kumamoto University, Kumamoto, Japan.
  • Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.
  • National Institute for Physiological Sciences (NIPS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan.
  • Exploratory Research Center on Life and Living Systems (ExCELLS), National Institutes of Natural Sciences, Okazaki, Aichi, Japan.
  • SOKENDAI (The Graduate University for Advanced Studies), Okazaki, Aichi, Japan.

ORCID-Profile: Yuri Kato, Motohiro Nishida

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Corporation
  • Grant-in-Aid for Scientific Research on Innovative Areas (A)
  • Japan Agency for Medical Research and Development
  • Joint Research of the Exploratory Research Center on Life and Living Systems (ExCELLS)
  • National Research Foundation of Korea (NRF) funded by the Korean government (MSIP)
  • Naito Foundation

Zitieren

APA

Kato, Y., Ariyoshi, K., Nohara, Y., Matsunaga, N., Shimauchi, T., Shindo, N., Nishimura, A., Mi, X., Kim, S. G., Ide, T., Kawanishi, E., Ojida, A., Nakashima, N., Mori, Y., & Nishida, M. (2024). Inhibition of dynamin‐related protein 1‐filamin interaction improves systemic glucose metabolism. British Journal of Pharmacology. https://doi.org/10.1111/bph.16487

Vancouver

Kato Y, Ariyoshi K, Nohara Y, Matsunaga N, Shimauchi T, Shindo N, et al. Inhibition of dynamin‐related protein 1‐filamin interaction improves systemic glucose metabolism. British Journal of Pharmacology. 2024. doi:10.1111/bph.16487

BibTeX
@article{Kato2024,
  author = {Kato, Yuri and Ariyoshi, Kohei and Nohara, Yasunobu and Matsunaga, Naoya and Shimauchi, Tsukasa and Shindo, Naoya and Nishimura, Akiyuki and Mi, Xinya and Kim, Sang Geon and Ide, Tomomi and Kawanishi, Eiji and Ojida, Akio and Nakashima, Naoki and Mori, Yasuo and Nishida, Motohiro},
  title = {Inhibition of dynamin‐related protein 1‐filamin interaction improves systemic glucose metabolism},
  journal = {British Journal of Pharmacology},
  year = {2024},
  doi = {10.1111/bph.16487}
}
Kostenlos starten →